The TSX stocks on our list have averaged 211% revenue growth over the past three years
SmallCapPower | April 30, 2018: As the TSX remains relatively range-bound, companies that have seen reliable growth could appear especially attractive. The TSX stocks on our list today have generated average revenue growth of 211%, outperforming their Canadian peers, which have returned a median of 6%.
Tidewater Midstream and Infrastructure Ltd. (TSX:TWM) – $1.31
Natural Gas Utilities
Tidewater Midstream is a Canada-based natural gas company operating in Alberta. The Company operates over 4,000km of pipelines, transporting over 1.5 Bcf/day. Over 75% of its earnings is sourced from long-term relationships with over 50 customers, including TransAlta (TSX:TA).
- Market Cap: $417.9 Million
- YTD Total Return: -13.2%
- Revenue 3 YR Hist Growth: 240.8%
- FY2018 Forward Revenue Growth: 11.9%
Athabasca Oil Corp. (TSX:ATH) – $1.66
Oil & Gas Exploration and Production
Athabasca Oil is a Canada-based light and thermal oil producer operating in Alberta. The Company aims to maintain its Montney light oil asset and expand its Duvernay light oil asset through a JV with Murphy Oil (NYSE:MUR). The Company also plans to maintain its Leismer thermal oil production platform, as well as ramp up production at its Hangingstone asset. In total, the Company produces ~40,000 boe/d at 90% oil and liquids, with ~1,250 mmboe in reserves.
- Market Cap: $817.2 Million
- YTD Total Return: 55.1%
- Revenue 3 YR Hist Growth: 229.3%
- FY2018 Forward Revenue Growth: -21.8%
Park Lawn Corp. (TSX:PLC) – $24.76
Park Lawn provides death-care services in Canada and the U.S. The Company provides cemeteries, crematoria, funeral homes, and chapels, on at at-need or pre-need basis. From 9 properties in 2013, the Company now operates 102 locations in the non-Maritimes provinces and six states. PLC aims to continue its rapid growth rate, ~65% through acquisitions and ~35% through organic growth.
- Market Cap: $385.5 Million
- YTD Total Return: 8.9%
- Revenue 3 YR Hist Growth: 217.6%
- FY2018 Forward Revenue Growth: 50.3%
Aurinia Pharmaceuticals Inc. (TSX:AUP) – $6.91
Biotechnology & Medical Research
Aurinia is a Canada-based biopharmaceutical company developing applications for voclosporin, an immunosuppressant drug. The Company’s primary drug is in Phase 3 development, aimed at treating lupus nephritis (LN), an autoimmune disease in the kidneys. The drug’s Stage 2 trials were the first active lupus nephritis to meet its treatment goals. Aurinia is also developing voclosporin solutions for focal segmental glomerulosclerosis, which causes kidney damage, and Dry Eye Syndrome, both in Phase 1. It also licenses its technology to other companies.
- Market Cap: $592.5 Million
- YTD Total Return: 20.8%
- Revenue 3 YR Hist Growth: 203.9%
- FY2018 Forward Revenue Growth: -48.0%
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below: